First-line (1L) trastuzumab deruxtecan (T-DXd)-based regimens in advanced HER2-expressing gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): Safety results from DESTINY-Gastric03 (DG-03) Part 2 arms D and F, and Part 4.

  • Janjigian, Yelena Y.; 
  • Shoji, Hirokazu; 
  • Kowalczyk, Anna; 
  • Rha, Sun Young; 
  • Pietrantonio, Filippo; 
  • ... Lee, Jeeyun; 
  • 외 14명
Citations

WEB OF SCIENCE

0
제목
First-line (1L) trastuzumab deruxtecan (T-DXd)-based regimens in advanced HER2-expressing gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): Safety results from DESTINY-Gastric03 (DG-03) Part 2 arms D and F, and Part 4.
저자
Janjigian, Yelena Y.; Shoji, Hirokazu; Kowalczyk, Anna; Rha, Sun Young; Pietrantonio, Filippo; Shitara, Kohei; Calvo Ferrandiz, Aitana; Van Laarhoven, Hanneke W. M.; Liu, Tianshu; Karaszewska, Boguslawa; Lee, Keun-Wook; Abdalla, Kathia Cristina; Chen, Eric Xueyu; Asselah, Jamil; Limon, M. Luisa; Scott, Megan; Lloyd, Caron; Nwazue, Eric; Rabbie, Roy; Lee, Jeeyun
DOI
10.1200/JCO.2026.44.16_suppl.4022
발행일
2026-06-01
유형
Meeting Abstract
저널명
Journal of Clinical Oncology
권
44
호
16_SUPPL